par Meyers, Michel;Mouna, Oumnia;Langouo Fontsa, Mireille 
Référence Current opinion in oncology, 37, 2, page (116-120)
Publication Publié, 2025-03-01

Référence Current opinion in oncology, 37, 2, page (116-120)
Publication Publié, 2025-03-01
Article révisé par les pairs
Résumé : | This review evaluates by analyzing recent studies whether pathological complete response (pCR) can be used as a reliable surrogate marker for overall survival (OS) in melanoma treated with neoadjuvant immunotherapy. |